Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?

Jordi Remon; Benjamin Besse

doi:10.1038/s41571-021-00574-1

Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?

Jordi Remon, Benjamin Besse

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	7-8
Nombre de pages	2
journal	Nature Reviews Clinical Oncology
Volume	19
Numéro de publication	1
Les DOIs	https://doi.org/10.1038/s41571-021-00574-1
état	Publié - 1 janv. 2022

Accès au document

10.1038/s41571-021-00574-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{25dc5d843b3d4c7dbf2726e5cc7921a8,

title = "Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?",

author = "Jordi Remon and Benjamin Besse",

note = "Funding Information: J.R. reports advisory roles for Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim, MSD, OSE Immunotherapeutics and Roche; has received travel funds from AstraZeneca, BMS, OSE Immuotherapeutics and Roche; and speaker{\textquoteright}s fees from Pfizer, all outside the submitted work. B.B. has received grants from Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharma, outside the submitted work.",

year = "2022",

month = jan,

day = "1",

doi = "10.1038/s41571-021-00574-1",

language = "English",

volume = "19",

pages = "7--8",

journal = "Nature Reviews Clinical Oncology",